{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:57:00Z","timestamp":1793350620997,"version":"4.5.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T00:00:00Z","timestamp":1592092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>STUDY QUESTION<\/jats:title>\n                    <jats:p>Does polycystic ovary syndrome (PCOS) confer an independent risk for the development of gestational diabetes mellitus (GDM), gestational hypertension (GHTN) and preeclampsia (PEC) based on analysis of the Healthcare Cost and Utilization Project Nationwide Inpatient Sample (HCUP-NIS) database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SUMMARY ANSWER<\/jats:title>\n                    <jats:p>After controlling for all potential confounding effects, women with PCOS are at a 2-fold higher risk of developing GDM, a 50% increased risk for the development of GHTN and a 30% increased risk of developing PEC than women without PCOS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                    <jats:p>Currently, there is evidence of an increased prevalence of maternal pregnancy complications in women with PCOS. However, there remain significant gaps in understanding how PCOS affects the development of GDM, GHTN and PEC. This is most likely due to the complex, multifactorial etiology of PCOS, its range of potential confounders for pregnancy complications and the variable methodology of studies that have been conducted. To date, the largest meta-analysis on this subject includes 11\u00a0565 women with PCOS analyzed for their risk of GDM and 5896 patients analyzed for their risk of PEC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                    <jats:p>This is a retrospective population-based study utilizing data from the HCUP-NIS over 11 years from 2004 to 2014. A dataset of all deliveries between 2004 and 2014 inclusively was created. Within this group, all deliveries to women with PCOS were identified as part of the study group (n\u2009=\u200914\u00a0882), and the remaining deliveries were categorized as non-PCOS births and comprised the reference group (n\u2009=\u20099\u00a0081\u00a0906).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                    <jats:p>The HCUP-NIS is the largest inpatient sample database in the USA and is comprised of hospital inpatient stays submitted by hospitals throughout the entire country. Each year, the database provides information relating to 7 million inpatient stays, including patient characteristics, diagnosis and procedures. The data are representative of \u223c20% of admissions to US hospitals across 48 states and the District of Columbia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                    <jats:p>At baseline, more pregnant women with PCOS were obese (22.3% vs. 3.5%, P\u2009&amp;lt;\u20090.001), had chronic hypertension (HTN) (8.4% vs. 1.8%, P\u2009&amp;lt;\u20090.001), had pregestational diabetes (4.1% vs. 0.9%, P\u2009&amp;lt;\u20090.001) and had treated thyroid disease (12.6% vs. 2.4%, P\u2009&amp;lt;\u20090.001). Women with PCOS were also more likely to have undergone IVF treatment (2.4% vs. 0.1%, P\u2009&amp;lt;\u20090.001), have multi-gestation pregnancies (5.9% vs. 1.5%, P\u2009&amp;lt;\u20090.001), and more multiple gestations (MGs) in the PCOS group were the result of IVF treatment than the non-PCOS groups (12.3% vs. 2.3%, P\u2009&amp;lt;\u20090.001). In all pregnancies, women with PCOS were more likely to develop gestational diabetes (adjusted odds ratio (aOR) 2.19, 95% CI 2.02\u20132.37), pregnancy associated HTN (aOR 1.38, 95% CI 1.27\u20131.50, P\u2009&amp;lt;\u20090.001), GHTN (aOR 1.47, 95% CI 1.31\u20131.64), PEC (aOR 1.29, 95% CI 1.14\u20131.45) and superimposed PEC (aOR 1.29, 95% CI 1.04\u20131.59) after controlling for confounding effects (age, race, income level, insurance type, obesity, IVF use, previous cesarean section, chronic HTN, pregestational diabetes, thyroid disease, MG, smoking and recreational drug use). Odds ratios were comparable between all pregnancies and singleton pregnancies only. In women pregnant with multiple fetuses, PCOS only conferred a statistically significant increased risk of developing GDM (aOR 2.33, 95% CI 1.92\u20132.83, P\u2009&amp;lt;\u20090.001). However, there was a trend toward an increased risk for developing pregnancy associated HTN (aOR 1.92, 95% CI 0.99\u20131.42, P\u2009=\u20090.058).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                    <jats:p>This is a retrospective analysis utilizing an administrative database which relies on the accuracy and consistency of the individuals coding the data. There are known limitations in how accurately hospital coding is able to capture perinatal conditions and complications, making it difficult to know with certainty that such events are accurate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                    <jats:p>Pregnant women with PCOS are at increased risk of adverse complications in pregnancy even when they do not present with other coexisting metabolic conditions. Furthermore, it is important to also consider the risk of all other coexisting metabolic conditions frequently encountered in PCOS women, as these risks are additive and place women with PCOS at significantly increased risk for adverse complications in pregnancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                    <jats:p>None.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/humrep\/deaa099","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T23:20:23Z","timestamp":1587511223000},"page":"1666-1674","source":"Crossref","is-referenced-by-count":151,"title":["Polycystic ovary syndrome as an independent risk factor for gestational diabetes and hypertensive disorders of pregnancy: a population-based study on 9.1 million pregnancies"],"prefix":"10.1093","volume":"35","author":[{"given":"Ginevra","family":"Mills","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, McGill University Health Centre, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Badeghiesh","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, McGill University Health Centre, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Suarthana","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, McGill University Health Centre, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitham","family":"Baghlaf","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, McGill University Health Centre, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H","family":"Dahan","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, McGill University Health Centre, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,14]]},"reference":[{"key":"2020071809163780500_deaa099-B1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.metabol.2017.09.016","article-title":"Polycystic ovarian syndrome (PCOS): long-term metabolic consequences","volume":"86","author":"Anagnostis","year":"2018","journal-title":"Metab Clin Exp"},{"key":"2020071809163780500_deaa099-B2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncpendmet0117","article-title":"How prevalent is metabolic syndrome in women with polycystic ovary syndrome?","volume":"2","author":"Azziz","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"2020071809163780500_deaa099-B3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.fertnstert.2016.05.009","article-title":"Introduction: determinants of polycystic ovary syndrome","volume":"106","author":"Azziz","year":"2016","journal-title":"Fertil Steril"},{"key":"2020071809163780500_deaa099-B4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2015.12.013","article-title":"Stein and Leventhal: 80 years on","volume":"214","author":"Azziz","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"2020071809163780500_deaa099-B5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/humupd\/dml036","article-title":"A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome","volume":"12","author":"Boomsma","year":"2006","journal-title":"Hum Reprod Update"},{"key":"2020071809163780500_deaa099-B6","doi-asserted-by":"crossref","first-page":"294","DOI":"10.23736\/S0391-1977.16.02482-2","article-title":"Cardiovascular disease in PCOS is related to severe insulin resistance, not mild","volume":"42","author":"Dahan","year":"2017","journal-title":"Minerva Endocrinol"},{"key":"2020071809163780500_deaa099-B7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s12020-019-01899-9","article-title":"Relationship among obesity, insulin resistance, and hyperinsulinemia in the polycystic ovary syndrome","volume":"64","author":"Dahan","year":"2019","journal-title":"Endocrine"},{"key":"2020071809163780500_deaa099-B8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.fertnstert.2017.06.015","article-title":"Increased rates of complications in singleton pregnancies of women previously diagnosed with polycystic ovary syndrome predominantly in the hyperandrogenic phenotype","volume":"108","author":"de Wilde","year":"2017","journal-title":"Fertil Steril"},{"key":"2020071809163780500_deaa099-B9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/09513590.2019.1631278","article-title":"Comparing pregnancy, childbirth, and neonatal outcomes in women with different phenotypes of polycystic ovary syndrome and healthy women: a prospective cohort study","volume":"36","author":"Foroozanfard","year":"2020","journal-title":"Gynecol Endocrinol"},{"key":"2020071809163780500_deaa099-B10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/cen.13828","article-title":"Comorbidities and complications of polycystic ovary syndrome: an overview of systematic reviews","volume":"89","author":"Gilbert","year":"2018","journal-title":"Clin Endocrinol"},{"key":"2020071809163780500_deaa099-B11","doi-asserted-by":"crossref","first-page":"B2","DOI":"10.1016\/j.ajog.2019.04.013","article-title":"SMFM special statement: state of the science on multifetal gestations: unique considerations and importance","volume":"221","author":"Grantz","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"2020071809163780500_deaa099-B12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1210\/jc.2014-3886","article-title":"The potential implications of a PCOS diagnosis on a woman\u2019s long-term health using data linkage","volume":"100","author":"Hart","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071809163780500_deaa099-B13","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1080\/13625187.2018.1483020","article-title":"Fertility management experiences of women with polycystic ovary syndrome in Australia","volume":"23","author":"Holton","year":"2018","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"2020071809163780500_deaa099-B14","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/humrep\/den482","article-title":"Long-term follow-up of patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve","volume":"24","author":"Hudecova","year":"2009","journal-title":"Hum Reprod"},{"key":"2020071809163780500_deaa099-B15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-0035-1571195","article-title":"Polycystic ovary syndrome, obesity, and pregnancy","volume":"34","author":"Joham","year":"2016","journal-title":"Semin Reprod Med"},{"key":"2020071809163780500_deaa099-B16","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/cen.13579","article-title":"Polycystic ovary syndrome and adverse pregnancy outcomes: current state of knowledge, challenges and potential implications for practice","volume":"88","author":"Khomami","year":"2018","journal-title":"Clin Endocrinol"},{"key":"2020071809163780500_deaa099-B17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/obr.12829","article-title":"Increased maternal pregnancy complications in polycystic ovary syndrome appear to be independent of obesity-a systematic review, meta-analysis, and meta-regression","volume":"20","author":"Khomami","year":"2019","journal-title":"Obes Rev"},{"key":"2020071809163780500_deaa099-B18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2011.03.021","article-title":"Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis","volume":"204","author":"Kjerulff","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"2020071809163780500_deaa099-B19","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1093\/humrep\/der229","article-title":"In women with polycystic ovary syndrome and obesity, loss of intra-abdominal fat is associated with resumption of ovulation","volume":"26","author":"Kuchenbecker","year":"2011","journal-title":"Hum Reprod"},{"key":"2020071809163780500_deaa099-B20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.fertnstert.2016.05.003","article-title":"Criteria, prevalence, and phenotypes of polycystic ovary syndrome","volume":"106","author":"Lizneva","year":"2016","journal-title":"Fertil Steril"},{"key":"2020071809163780500_deaa099-B21","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1210\/jc.2005-2430","article-title":"Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome","volume":"91","author":"Lo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071809163780500_deaa099-B22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.preghy.2017.12.006","article-title":"Polycystic ovary syndrome, body mass index and hypertensive disorders in pregnancy","volume":"11","author":"Lonnebotn","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"2020071809163780500_deaa099-B23","first-page":"1","article-title":"Complicating conditions associated with childbirth, by delivery method and payer, 2011: statistical brief #173","author":"Moore","year":"2006","journal-title":"Healthcare Cost and Utilization Project (HCUP) Statistical Briefs"},{"key":"2020071809163780500_deaa099-B24","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1530\/EC-18-0076","article-title":"Polycystic ovary syndrome and risk factors for gestational diabetes","volume":"7","author":"Mustaniemi","year":"2018","journal-title":"Endocr Connect"},{"key":"2020071809163780500_deaa099-B25","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(07)61345-2","article-title":"Polycystic ovary syndrome","volume":"370","author":"Norman","year":"2007","journal-title":"Lancet"},{"key":"2020071809163780500_deaa099-B26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.diabres.2018.04.030","article-title":"Polycystic ovary syndrome and hyperglycaemia in pregnancy. A narrative review and results from a Prospective Danish Cohort Study","volume":"145","author":"Palm","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"2020071809163780500_deaa099-B27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/humupd\/dmv029","article-title":"Pregnancy complications in women with polycystic ovary syndrome","volume":"21","author":"Palomba","year":"2015","journal-title":"Human Reproduction Update"},{"key":"2020071809163780500_deaa099-B28","doi-asserted-by":"crossref","first-page":"754","DOI":"10.23736\/S0026-4784.18.04230-2","article-title":"Pregnancy complications in infertile patients with polycystic ovary syndrome: updated evidence","volume":"70","author":"Palomba","year":"2018","journal-title":"Minerva Ginecol"},{"key":"2020071809163780500_deaa099-B29","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.fertnstert.2009.10.043","article-title":"Pregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes","volume":"94","author":"Palomba","year":"2010","journal-title":"Fertil Steril"},{"key":"2020071809163780500_deaa099-B30","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/humrep\/dez159","article-title":"Fecundity among women with polycystic ovary syndrome (PCOS)\u2014a population-based study","volume":"34","author":"Persson","year":"2019","journal-title":"Human Reproduction"},{"key":"2020071809163780500_deaa099-B31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1477-7827-11-56","article-title":"Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"11","author":"Qin","year":"2013","journal-title":"Reprod Biol Endocrinol"},{"key":"2020071809163780500_deaa099-B32","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1210\/jc.2015-2682","article-title":"Contemporary reproductive outcomes for patients with polycystic ovary syndrome: a retrospective observational study","volume":"101","author":"Rees","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071809163780500_deaa099-B33","first-page":"252","article-title":"Suitability of the National Health Care Surveys to examine behavioral health services associated with polycystic ovary syndrome","volume":"45","author":"Sanchez","year":"2018","journal-title":"J Behav Health Serv Res"},{"key":"2020071809163780500_deaa099-B34","doi-asserted-by":"crossref","first-page":"9847057","DOI":"10.1155\/2019\/9847057","article-title":"The association of polycystic ovary syndrome and gestational hypertensive disorders in a diverse community-based cohort","volume":"2019","author":"Schneider","year":"2019","journal-title":"J Pregnancy"},{"key":"2020071809163780500_deaa099-B35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.rbmo.2019.03.203","article-title":"A meta-analysis of pregnancy-related outcomes and complications in women with polycystic ovary syndrome undergoing IVF","volume":"39","author":"Sha","year":"2019","journal-title":"Reprod Biomed Online"},{"key":"2020071809163780500_deaa099-B36","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.fertnstert.2015.11.019","article-title":"Pregnancy outcomes in women with polycystic ovary syndrome undergoing in vitro fertilization","volume":"105","author":"Sterling","year":"2016","journal-title":"Fertil Steril"},{"key":"2020071809163780500_deaa099-B37","first-page":"300","article-title":"Effect of obesity on clinical parameters and pregnancy rates in women with polycystic ovary syndrome undergoing ovulation induction cycles","volume":"62","author":"Tokmak","year":"2017","journal-title":"J Reprod Med"},{"key":"2020071809163780500_deaa099-B38","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.fertnstert.2008.06.045","article-title":"Risk of gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and a meta-analysis","volume":"92","author":"Toulis","year":"2009","journal-title":"Fertil Steril"},{"key":"2020071809163780500_deaa099-B39","doi-asserted-by":"crossref","first-page":"116940","DOI":"10.1016\/j.lfs.2019.116940","article-title":"Hyperandrogenemia and insulin resistance: the chief culprit of polycystic ovary syndrome","volume":"236","author":"Wang","year":"2019","journal-title":"Life Sci"},{"key":"2020071809163780500_deaa099-B40","doi-asserted-by":"crossref","first-page":"e4863","DOI":"10.1097\/MD.0000000000004863","article-title":"Association between polycystic ovary syndrome and the risk of pregnancy complications A PRISMA-compliant systematic review and meta-analysis","volume":"95","author":"Yu","year":"2016","journal-title":"Medicine"},{"key":"2020071809163780500_deaa099-B41","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.gendis.2018.03.001","article-title":"Evaluation of DNA damage profile in obese women and its association to risk of metabolic syndrome, polycystic ovary syndrome and recurrent preeclampsia","volume":"5","author":"Zaki","year":"2018","journal-title":"Genes Dis"},{"key":"2020071809163780500_deaa099-B42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/09513590.2015.1111327","article-title":"Visceral adiposity index as a predictor of clinical severity and therapeutic outcome of PCOS","volume":"32","author":"Zheng","year":"2016","journal-title":"Gynecol Endocrinol"},{"key":"2020071809163780500_deaa099-B43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13098-019-0462-6","article-title":"Early pregnancy metabolic factors associated with gestational diabetes mellitus in normal-weight women with polycystic ovary syndrome: a two-phase cohort study","volume":"11","author":"Zheng","year":"2019","journal-title":"Diabetol Metab Syndr"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/35\/7\/1666\/33511344\/deaa099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/35\/7\/1666\/33511344\/deaa099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T19:44:39Z","timestamp":1666381479000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/35\/7\/1666\/5857279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,14]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,6,14]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deaa099","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,6,14]]}}}